keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant chemotherapy of NSCLC

keyword
https://www.readbyqxmd.com/read/28129775/cmtm1_v17-is-associated-with-chemotherapy-resistance-and-poor-prognosis-in-non-small-cell-lung-cancer
#1
Jiahui Si, Panpan Zhang, Dan Tian, Xing Wang, Yuanyuan Ma, Jianzhi Zhang, Lu Wang, Yue Yang
BACKGROUND: Considering neoadjuvant chemotherapy (NAC) prior to surgery could shrink and reduce the primary tumor and distant micro-metastases to reduce the high relapses rates, NAC has been an accepted therapeutic management for patients with non-small cell lung cancer (NSCLC). CMTM1_v17 is highly expressed in human testis tissues and solid tumor tissues but relatively low expression was obtained in the corresponding normal tissues. This study aims to investigate the significance of CMTM1_v17 in NSCLC and its association with platinum-based NAC efficacy...
January 28, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28126333/first-line-ceritinib-versus-platinum-based-chemotherapy-in-advanced-alk-rearranged-non-small-cell-lung-cancer-ascend-4-a-randomised-open-label-phase-3-study
#2
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, Yi-Long Wu, Luis Paz-Ares, Juergen Wolf, Sarayut L Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu, Maximillian Hochmair, Alexis B Cortot, Chun-Ming Tsai, Denis Moro-Sibilot, Rosario G Campelo, Tracey McCulloch, Paramita Sen, Margaret Dugan, Serafino Pantano, Fabrice Branle, Cristian Massacesi, Gilberto de Castro
BACKGROUND: The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the efficacy and safety of ceritinib versus platinum-based chemotherapy in these patients. METHODS: This randomised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC was done in 134 centres across 28 countries. Eligible patients were assigned via interactive response technology to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m(2) or carboplatin AUC 5-6 plus pemetrexed 500 mg/m(2)] every 3 weeks for four cycles followed by maintenance pemetrexed); randomisation was stratified by World Health Organization performance status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at screening...
January 23, 2017: Lancet
https://www.readbyqxmd.com/read/28102506/a-comparison-of-flt-to-fdg-pet-ct-in-the-early-assessment-of-chemotherapy-response-in-stages-ib-iiia-resectable-nsclc
#3
John P Crandall, Abdel K Tahari, Rosalyn A Juergens, Julie R Brahmer, Charles M Rudin, Giuseppe Esposito, Deepa S Subramaniam, Michael V Knopp, Nathan C Hall, Prateek Gajwani, Jeffrey P Leal, Martin A Lodge, Joo H O, Edward W Gabrielson, Lalitha K Shankar, Richard L Wahl
BACKGROUND: The aim of this study was to compare the percentage change in (18)F-fluorothymidine (FLT) standard uptake value (SUV) between baseline and after one cycle of chemotherapy in patients categorized by RECIST 1.1 computed tomography (CT) as responders or non-responders after two cycles of therapy. Change in (18)F-fluorodeoxyglucose (FDG) uptake was also compared between these time points. Nine patients with newly diagnosed, operable, non-small cell lung cancer (NSCLC) were imaged with FDG positron emission tomography/CT (PET), FLT PET/CT, and CT at baseline, following one cycle of neoadjuvant therapy (75 mg/m(2) docetaxel + 75 mg/m(2) cisplatin), and again after the second cycle of therapy...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28008145/msh2-brca1-expression-as-a-dna-repair-signature-predicting-survival-in-early-stage-lung-cancer-patients-from-the-ifct-0002-phase-3-trial
#4
Guénaëlle Levallet, Fatéméh Dubois, Pierre Fouret, Martine Antoine, Solenn Brosseau, Emmanuel Bergot, Michèle Beau-Faller, Valérie Gounant, Elisabeth Brambilla, Didier Debieuvre, Olivier Molinier, Françoise Galateau-Sallé, Julien Mazieres, Elisabeth Quoix, Jean-Louis Pujol, Denis Moro-Sibilot, Alexandra Langlais, Franck Morin, Virginie Westeel, Gérard Zalcman
INTRODUCTION: DNA repair is a double-edged sword in lung carcinogenesis. When defective, it promotes genetic instability and accumulated genetic alterations. Conversely these defects could sensitize cancer cells to therapeutic agents inducing DNA breaks. METHODS: We used immunohistochemistry (IHC) to assess MSH2, XRCC5, and BRCA1 expression in 443 post-chemotherapy specimens from patients randomized in a Phase 3 trial, comparing two neoadjuvant regimens in 528 Stage I-II non-small cell lung cancer (NSCLC) patients (IFCT-0002)...
December 19, 2016: Oncotarget
https://www.readbyqxmd.com/read/27908619/correlation-of-dna-repair-gene-polymorphisms-with-clinical-outcome-in-patients-with-locally-advanced-non-small-cell-lung-cancer-receiving-induction-chemotherapy-followed-by-surgery
#5
Mariacarmela Santarpia, Jose Luis Ramirez, Itziar de Aguirre, Pilar Garrido, Maria Pérez Cano, Cristina Queralt, Jose Luis Gonzalez-Larriba, Amelia Insa, Mariano Provencio, Dolores Isla, Carlos Camps, Remei Blanco, Teresa Moran, Rafael Rosell
OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. MATERIALS AND METHODS: A total of 109 patients with stage IIIA and IIIB NSCLC were prospectively genotyped to examine a potential association between XPD 312 (aspartic acid [Asp]/asparagine [Asn]), XPD 751 (lysine [Lys]/glutamine [Gln]), and RRM1 (-37 C/A) polymorphisms with response and survival...
November 9, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27793776/case-control-study-smoking-history-affects-the-production-of-tumor-antigen-specific-antibodies-ny-eso-1-in-patients-with-lung-cancer-in-comparison-with-cancer-disease-free-group
#6
Dagmar Myšíková, Irena Adkins, Nad'a Hradilová, Ondřej Palata, Jan Šimonek, Jiří Pozniak, Jan Kolařík, Anna Skallová-Fialová, Radek Špíšek, Robert Lischke
INTRODUCTION: Lung cancer is the leading cause of cancer mortality worldwide; therefore, understanding the biological or clinical role of tumor-associated antigens and autoantibodies is of eminent interest for designing antitumor immunotherapeutic strategies. METHODS: Here we prospectively analyzed the serum frequencies of New York esophageal squamous cell carcinoma 1 (NY-ESO-1), human epidermal growth factor 2/neu, and melanoma-associated antigen A4 (MAGE-A4) antibodies and expression of the corresponding antigens in tumors of 121 patients with NSCLC undergoing an operation without prior neoadjuvant chemotherapy and compared them with those in 57 control age-matched patients with no history of a malignant disease...
February 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27677242/neoadjuvant-chemoradiotherapy-vesus-chemotherapy-alone-followed-by-surgery-for-resectable-stage-iii-non-small-cell-lung-cancer-a-meta-analysis
#7
Shan Xian Guo, Yan Jian, Ying Lan Chen, Yun Cai, Qing Yuan Zhang, Fang Fang Tou
Neoadjuvant Chemotherapy has been used for the stage III of non-small cell lung cancer (NSCLC) and has shown good clinical effects. However, the survival benefits of radiation therapy added in induction regimens remains controversial. We therefore conducted a meta-analysis of the published clinical trials to quantitatively evaluate the benefit of preoperative chemoradiotherapy. After searching the database of Pubmed, CNKI, EMBASE, ESMO, The Cochrane Library databases, The American Society of Clinical Oncology and Clinical Trials...
September 28, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27568486/have-adjuvant-tyrosine-kinase-inhibitors-lost-their-shine
#8
COMMENT
Joshua K Sabari, Jamie E Chaft
Despite broad advances in molecularly targeted therapies, lung cancer remains the leading cause of cancer related mortality in the United States. Epidermal growth factor receptor (EGFR) mutations occur in approximately 17% of advanced non-small cell lung cancer (NSCLC) in the US population. The remarkable efficacy of small-molecule EGFR tyrosine kinase inhibitors (TKIs) in this unique subset of patients has revolutionized the therapeutic approach to lung cancer. The success of these agents in the metastatic setting leads to the logical question of what role these drugs may have in the adjuvant setting for patients with earlier stage disease...
August 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27566586/combining-antiangiogenic-therapy-with-neoadjuvant-chemotherapy-increases-treatment-efficacy-in-stage-iiia-n2-non-small-cell-lung-cancer-without-increasing-adverse-effects
#9
Xiaoliang Zhao, Yanjun Su, Jian You, Liqun Gong, Zhenfa Zhang, Meng Wang, Zhenqing Zhao, Zhen Zhang, Xiaolin Li, Changli Wang
To evaluate the safety and efficacy of combining Endostar antiangiogenic therapy with neoadjuvant chemotherapy for the treatment of stage IIIA (N2) NSCLC, we conducted a randomized, controlled, open-label clinical study of 30 NSCLC patients. Patients were randomly assigned to the test or control groups, which received either two cycles of an NP neoadjuvant chemotherapy regimen combined with Endostar or the NP regimen alone, respectively, at a 2:1 ratio. Efficacy was assessed after 3 weeks, and surgical resection occurred within 4 weeks, in the 26 patients who successfully completed treatment...
September 20, 2016: Oncotarget
https://www.readbyqxmd.com/read/27565935/altered-expression-of-programmed-death-ligand-1-after-neo-adjuvant-chemotherapy-in-patients-with-lung-squamous-cell-carcinoma
#10
Zhengbo Song, Xinmin Yu, Yiping Zhang
OBJECTIVE: Programmed death-ligand 1 (PD-L1) is known to be over-expressed in non-small cell lung cancer (NSCLC). However, the impact of chemotherapy on the altered status of PD-L1 expression has not been examined for NSCLC. The present study was intended to examine the impact of neoadjuvant chemotherapy on PD-L1 expression and its prognostic significance in lung squamous cell carcinoma (SCC). PATIENTS AND METHODS: Matched tumor samples were obtained from 76 SCC patients prior to and after neoadjuvant chemotherapy...
September 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27462164/targeted-therapy-for-localized-non-small-cell-lung-cancer-a-review
#11
REVIEW
Nicolas Paleiron, Olivier Bylicki, Michel André, Emilie Rivière, Frederic Grassin, Gilles Robinet, Christos Chouaïd
Targeted therapies have markedly improved the management of patients with advanced non-small-cell lung cancer (NSCLC), but their efficacy in localized NSCLC is less well established. The aim of this review is to analyze trials of targeted therapies in localized NSCLC. In patients with wild-type EGFR, tyrosine kinase inhibitors have shown no efficacy in Phase III trials. Few data are available for EGFR-mutated localized NSCLC, as routine biological profiling is not recommended. Available studies are small, often retrospectives, and/or conducted in a single-center making it difficult to draw firm conclusions...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27378175/optimizing-survival-of-patients-with-marginally-operable-stage-iiia-non-small-cell-lung-cancer-receiving-chemoradiotherapy-with-or-without-surgery
#12
Kai-Lin Yang, Yih-Chen Chang, Hui-Ling Ko, Mau-Shin Chi, Hsin-Ell Wang, Pei-Sung Hsu, Chen-Chun Lin, Diana Yu-Wung Yeh, Shang-Jyh Kao, Jiunn-Song Jiang, Kwan-Hwa Chi
BACKGROUND: For marginally operable stage IIIA non-small-cell lung cancer (NSCLC), surgery might not be done as planned after neoadjuvant concurrent chemoradiotherapy (CCRT) for reasons (unresectable or medically inoperable conditions, or patient refusal). This study aims to investigate the outcomes of a phased CCRT protocol established to maximize the operability of marginally operable stage IIIA NSCLC and to care for reassessed inoperable patients, in comparison with continuous-course definitive CCRT...
June 8, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27338051/gas5-modulated-autophagy-is-a-mechanism-modulating-cisplatin-sensitivity-in-nsclc-cells
#13
N Zhang, G-Q Yang, X-M Shao, L Wei
OBJECTIVE: In this study, we investigated the association between lncRNA GAS5 and cisplatin (DDP) resistance in NSCLC and further studied the regulative effect of GAS5 on autophagy and DDP resistance. PATIENTS AND METHODS: GAS5 expression in cancerous and adjacent normal tissues from 15 NSCLC patients received neoadjuvant chemotherapy and the following surgery were measured using qRT-PCR analysis. GAS5 gain-and-loss study was performed using A549 and A549/DDP cells as an in-vitro model to investigate the effect of GAS5 on autophagy and cisplatin sensitivity...
June 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27261916/neoadjuvant-therapy-in-non-small-cell-lung-cancer
#14
REVIEW
Yifan Zheng, Michael T Jaklitsch, Raphael Bueno
Locally advanced (stage IIIA) non-small cell lung cancer (NSCLC) is confined to the chest, but requires more than surgery to maximize cure. Therapy given preoperatively is termed neoadjuvant, whereas postoperative therapy is termed adjuvant. Trimodality therapy (chemotherapy, radiation, and surgery) has become the standard treatment regimen for resectable, locally advanced NSCLC. During the past 2 decades, several prospective, randomized, and nonrandomized studies have explored various regimens for preoperative treatment of NSCLC...
July 2016: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27232513/neoadjuvant-intratumoral-immuno-gene-therapy-for-non-small-cell-lung-cancer
#15
Jarrod D Predina, Jane Keating, Ollin Venegas, Sarah Nims, Sunil Singhal
Non-small Cell Lung Cancer (NSCLC) remains a deadly disease despite aggressive treatment protocols which incorporate chemotherapy, radiation and surgery. These traditional approaches have reached a plateau in therapeutic benefit. There is emerging evidence suggesting that immunotherapy can serve as an alternative treatment modality for NSCLC. Our group has nearly two decades of experience involving immuno-gene therapy with Ad.hIFN-α and Ad.hIFN-β in human mesothelioma trials, and has observed both safety and efficacy in treatment of Thoracic malignancies...
April 2016: Discovery Medicine
https://www.readbyqxmd.com/read/27230669/resected-pn1-non-small-cell-lung-cancer-recurrence-patterns-and-nodal-risk-factors-may-suggest-selection-criteria-for-post-operative-radiotherapy
#16
Paolo Borghetti, Fernando Barbera, Marco Lorenzo Bonù, Francesca Trevisan, Stefano Ciccarelli, Paola Vitali, Marta Maddalo, Luca Triggiani, Nadia Pasinetti, Sara Pedretti, Bartolomea Bonetti, Gianluca Pariscenti, Andrea Tironi, Alberto Caprioli, Michela Buglione, Stefano Maria Magrini
PURPOSE: To describe the pattern of recurrence in resected pN1 non-small cell lung cancer (NSCLC) and to identify factors predicting an increased risk of locoregional recurrence (LR) or distant metastasis (DM) to define a selected population who may benefit from postoperative radiotherapy (PORT). METHODS: 285 patients with resected pN1 NSCLC were identified. Patients with positive surgical margins, undergoing neoadjuvant treatment or PORT, were excluded. LR was defined as first event of recurrence at the surgical bed, ipsilateral hilum or mediastinum, and other sites were considered as DM...
September 2016: La Radiologia Medica
https://www.readbyqxmd.com/read/27105513/genetic-changes-of-non-small-cell-lung-cancer-under-neoadjuvant-therapy
#17
Arne Warth, Volker Endris, Albrecht Stenzinger, Roland Penzel, Alexander Harms, Thomas Duell, Amir Abdollahi, Michael Lindner, Peter Schirmacher, Thomas Muley, Hendrik Dienemann, Ludger Fink, Alicia Morresi-Hauf, Nicole Pfarr, Wilko Weichert
BACKGROUND: Large scale sequencing efforts defined common molecular alterations in non-small cell lung cancer (NSCLC) and revealed potentially druggable mutations. Yet, systematic data on the changes of the respective molecular profiles under standard therapy in NSCLC are limited. RESULTS: 14 out of 68 observed coding mutations (21%) and 6 out of 33 (18%) copy number variations (CNV) were lost or gained during therapy. Mutational and CNV changes clustered in 6/37 (16%) and 3/37 (8%) patients...
May 17, 2016: Oncotarget
https://www.readbyqxmd.com/read/27035568/-neoadjuvant-radiochemotherapy-followed-by-curative-resection-in-patients-with-advanced-non-small-cell-lung-cancer-in-stage-iiia-iiib-prognostic-factors-and-results
#18
W Schreiner, W Dudek, S Lettmaier, S Gavrychenkova, R Rieker, R Fietkau, H Sirbu
The role of surgical lung resection following neo-adjuvant radio-chemotherapy (RCT) in patients with locally advanced non-small cell lung cancer (NSCLC) is yet not clearly defined. The aim of our study was to analyze the postoperative survival and to identify relevant prognostic factors. 46 patients underwent curative resections after neo-adjuvant RCT for locally advanced NSCLC (IIIA/IIIB) between February 2008 and February 2015. A retrospective data analysis regarding preoperative regression status, perioperative mortality, postoperative survival, patho-histological remission, relapse pattern and other prognostic factors was performed...
June 2016: Zentralblatt Für Chirurgie
https://www.readbyqxmd.com/read/26996551/apolipoproteins-as-differentiating-and-predictive-markers-for-assessing-clinical-outcomes-in-patients-with-small-cell-lung-cancer
#19
Jian Shi, Huichai Yang, Xiaoyang Duan, Lihua Li, Lulu Sun, Qian Li, Junjun Zhang
PURPOSE: The present study aimed to investigate the value of apolipoproteins, including ApoA-1, ApoC-III, and ApoE, in patients with small cell lung cancer (SCLC) as potential biomarkers for diagnosis, prognosis, and cancer progression. MATERIALS AND METHODS: Lung samples were collected from 89 patients with SCLC. Nineteen lung samples from non-small cell lung cancer (NSCLC) patients and 12 normal lung tissues were used as controls. Expression profiles of ApoA-1, ApoC-III, and ApoE in different samples were examined using immunohistochemical methods, and the expression levels were correlated with cancer types, treatment, and outcomes using chi-square and Mann-Whitney tests...
May 2016: Yonsei Medical Journal
https://www.readbyqxmd.com/read/26955282/neoadjuvant-chemoradiotherapy-or-chemotherapy-followed-by-surgery-is-superior-to-that-followed-by-definitive-chemoradiation-or-radiotherapy-in-stage-iiia-n2-nonsmall-cell-lung-cancer-a-meta-analysis-and-system-review
#20
Xiao-Ling Xu, Li Dan, Wei Chen, Shuang-Mei Zhu, Wei-Min Mao
BACKGROUND: Approximately 30% of all cases of nonsmall-cell lung cancer (NSCLC) are of a locally advanced (IIIA or IIIB) stage. However, surgical therapy for patients with stage IIIA (N2) NSCLC is associated with a disappointing 5-year survival rate. The optimal treatment for stage IIIA (N2) NSCLC is still in dispute. METHODS: A literature search was performed in the PubMed, Embase, and MEDLINE databases (last search updated in March 2015), and a meta-analysis of the available data was conducted...
2016: OncoTargets and Therapy
keyword
keyword
52783
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"